Amgen Stock Forecast, Price & News

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Amgen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View analyst ratings for Amgen or view top-rated stocks.

Wall Street analysts have given Amgen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amgen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Amgen.

Amgen will be holding an earnings conference call on Tuesday, August 3rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "1682169".

Amgen Inc. (NASDAQ:AMGN) announced its earnings results on Monday, April, 26th. The medical research company reported $3.70 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.05 by $0.35. The medical research company had revenue of $5.90 billion for the quarter, compared to analysts' expectations of $6.30 billion. Amgen had a net margin of 28.16% and a trailing twelve-month return on equity of 93.84%. Amgen's quarterly revenue was down 4.2% on a year-over-year basis. During the same period last year, the firm posted $4.17 earnings per share.
View Amgen's earnings history.

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AMGN shares have increased by 21.6% and is now trading at $241.54.
View which stocks have been most impacted by COVID-19.

Amgen declared a quarterly dividend on Friday, July 30th. Stockholders of record on Tuesday, August 17th will be given a dividend of $1.76 per share on Wednesday, September 8th. This represents a $7.04 annualized dividend and a dividend yield of 2.91%.
View Amgen's dividend history.

Amgen pays an annual dividend of $7.04 per share and currently has a dividend yield of 2.91%. Amgen does not yet have a strong track record of dividend growth. The dividend payout ratio of Amgen is 42.41%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 39.09% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

Amgen updated its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share (EPS) guidance of 16.000-17.000 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.800. The company issued revenue guidance of $25.80 billion-$26.60 billion, compared to the consensus revenue estimate of $26.41 billion.

22 equities research analysts have issued 12-month price targets for Amgen's stock. Their forecasts range from $185.00 to $301.00. On average, they anticipate Amgen's share price to reach $250.00 in the next twelve months. This suggests a possible upside of 3.5% from the stock's current price.
View analysts' price targets for Amgen or view top-rated stocks among Wall Street analysts.

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amgen include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Novavax (NVAX), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Halozyme Therapeutics (HALO).
View all of AMGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (0.30%), Sarasin & Partners LLP (0.20%), Smead Capital Management Inc. (0.09%), Bartlett & Co. LLC (0.07%), Boston Trust Walden Corp (0.03%) and Zurcher Kantonalbank Zurich Cantonalbank (0.03%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, Nancy A Grygiel, R Sanders Williams and Ronald D Sugar.
View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., PGGM Investments, State of Michigan Retirement System, Baldwin Brothers Inc. MA, Exchange Traded Concepts LLC, Avalon Investment & Advisory, Ziegler Capital Management LLC, and Unigestion Holding SA. Company insiders that have sold Amgen company stock in the last year include Jonathan P Graham, Nancy A Grygiel, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen or view top insider-selling stocks.

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Smead Capital Management Inc., Advisors Asset Management Inc., Calamos Advisors LLC, Transform Wealth LLC, Rathbone Brothers plc, MUFG Securities EMEA plc, and IFM Investors Pty Ltd.
View insider buying and selling activity for Amgen or or view top insider-buying stocks.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMGN stock can currently be purchased for approximately $241.54.

Amgen has a market capitalization of $138.78 billion and generates $25.42 billion in revenue each year. The medical research company earns $7.26 billion in net income (profit) each year or $16.60 on an earnings per share basis.

Amgen employs 24,300 workers across the globe.

The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen (Europe) GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen Manufacturing Limited, Amgen Research (Munich) GmbH, Amgen Rockville Inc., Amgen S.A.S., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology (Ireland) Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Synergen, and Tularik.

Amgen was founded in 1980.

The official website for Amgen is www.amgen.com.

Amgen is headquartered at ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at (805) 447-1000 or via email at [email protected]